Recombinant canarypox virus-based vaccine (Sanofi Pasteur)

N/A

Report date: 2023/04/25 13:50:18

Base Information

Drug NameRecombinant canarypox virus-based vaccine (Sanofi Pasteur)
Drug Alias NameALVACCEA/B7.1vaccineALVAC-CEA/B7.1
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionCluster of differentiation 80 stimulantsCarcinoembryonic antigen stimulants
TargetsCluster of differentiation 80Carcinoembryonic antigen
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTherion BiologicsSanofi Pasteur
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTherion BiologicsSanofi PasteurNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursColorectal NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A